Építés alatt – nem éles oldal
Belépés
Résztvevőt keres2. fázis

A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)

A legfontosabb adatok

Ki végzi
Institute of Hematology & Blood Diseases Hospital, China
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
60 fő, tervezett
Kezdés
2023. dec. 1.
Várható befejezés
2026. nov.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Obinutuzumab Injection [Gazyva]
A regiszteradat frissítve
2025. február 24.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for children aged 12 to 18 with primary immune thrombocytopenia (ITP), a low platelet count caused by the immune system. Their disease did not respond well to steroid treatment or came back after it. They will receive Obinutuzumab.

Életkor
12 to 18 years
Nem
All sexes
A betegség stádiuma
Persistent or chronic primary ITP. Platelet count below 30 X 10^9/L, measured at least 2 times during screening, at least 1 week apart, and within 2 days before treatment. ECOG score of 2 or less (able to care for yourself). Heart function class 2 or less. Liver and kidney tests below 1.5 times the upper normal limit.
Korábbi kezelés
Steroid (hormone) treatment failed, the disease came back, or the person depends on steroids. Emergency ITP treatment (such as methylprednisolone, platelet transfusion, IVIG) must have ended at least 2 weeks before. Maintenance steroids (0.5mg/kg prednisone or less) or TPO receptor agonists must be at a stable dose for at least 4 weeks. Azathioprine, danazol, cyclosporin A, tacrolimus, sirolimus must be stopped at least 4 weeks before. Rituximab must have ended more than 3 months before. Spleen removal must be more than 6 months before.

A részvétel fő kizáró okai

  • Low platelets caused by another disease, such as connective tissue disease, bone marrow failure, cancer, lymphoma, drugs or inherited conditions
  • HIV, or active or uncontrolled infections such as hepatitis B, hepatitis C, cytomegalovirus, EB virus or syphilis
  • Severe bleeding, such as coughing blood, stomach bleeding or bleeding in the brain
  • Any blood clot in veins or arteries, or heart disease needing treatment
  • Past solid cancer, stem cell transplant or organ transplant, or taking antiplatelet drugs

A regiszter feltételei, szó szerint

Mind a 24 feltétel megnézéseKevesebb

Ki vehet részt

  • Age 12-18 years old, male or female
  • Conform to the diagnostic criteria of persistent or chronic immune Thrombocytopenia (ITP)
  • With a platelet count of <30 X 10\^9/L measured within 2 days prior to administration(Platelet counts were measured at least 2 times during screening (at least 1 week apart) with platelets<30 X 10\^9/L)
  • Failure or recurrence of previous hormonal therapy or hormone dependence
  • The previous emergency treatment of ITP (e.g. methylprednisolone, platelet transfusion, IVIG transfusion) must be completed at least 2 weeks before the first administration
  • Signed and dated written informed consent
  • With Liver and kidney function<1.5×upper limit of normal, such as ALT、AST,BUN,Cre,etc
  • ECOG physical state score ≤ 2 points
  • Cardiac function of the New York Society of Cardiac Function ≤ 2
  • Patients receiving maintenance treatment (including corticosteroids (less than or equal to 0.5mg/kg prednisone), TPO receptor agonists, etc.) must have a stable dose at least 4 weeks before the first administration, and azathioprine, danazol, cyclosporin A, tacrolimus, sirolimus, etc. must be stopped at least 4 weeks before the first administration; The end of rituximab treatment was>3 months;More than 6 months after splenectomy

Ki nem vehet részt

  • Patients taking antiplatelet drugs at the same time
  • Subjects with primary disease of important organs (liver, kidney, heart, etc.), or with immune system diseases
  • Secondary thrombocytopenia caused by various reasons, such as connective tissue disorders, bone marrow hematopoietic failure disease, myelodysplastic syndrome, malignancy, drugs, inherited thrombocytopenia, common variable immune deficiency, lymphoma, etc
  • Subjects infected with human immunodeficiency virus (HIV)
  • Uncontrollable or active infections during the screening period, including hepatitis B, hepatitis C, cytomegalovirus, EB virus, or positive syphilis antigen
  • Subjects with extensive and severe bleeding, such as hemoptysis, upper gastrointestinal hemorrhage, intracranial hemorrhage
  • Subjects with heart disease that requires treatment or hypertension that has been judged by researchers to be poorly controlled currently
  • Subjects with any venous or arterial thrombosis, atherosclerosis, and other diseases
  • Subjects with a history of malignant solid tumor or have received allogeneic stem cell transplantation or organ transplantation
  • Subjects with mental disorders who are unable to sign normal informed consent and conduct trials and follow-up
  • Subjects with other serious diseases that may limit their participation in this trial (diabetes; severe cardiac insufficiency; myocardial obstruction or unstable arrhythmia or unstable angina pectoris in the last 6 months; gastric ulcer; active autoimmune disease, etc.)
  • Subjects with septicemia or other irregular bleeding
  • Any medical history or condition that the investigator deems unsuitable for participation in the study
  • Subjects whose toxic symptoms caused by pre-trial treatment have not disappeared

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 12 és 18 év között vagy?

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

To evaluate the safety and efficacy of Obinutuzumab in the treatment of pediatric primary immune thrombocytopenia in patients who have not responded adequately or relapsed after first-line glucocorticoid treatment.

A vizsgálat csoportja

  • Intervention (Obinutuzumab)A vizsgált kezelés

    60 enrolled subjects: one infusion

    Kezelés: Obinutuzumab Injection [Gazyva]

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Prospective, One-arm and Open Clinical Study to Assess Safety and Efficacy of Anti-Human CD20 Monoclonal Antibody Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Illeszkedési kérdések
Forrás: NCT06094881: ki vehet részt
A regiszteradat frissítve
2025. február 24.
Építés alatt, nem éles – A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP) (NCT06094881) – Frontlight Research